Lemtrada FDA Approval History
FDA Approved: Yes (First approved November 14, 2014)
Brand name: Lemtrada
Generic name: alemtuzumab
Dosage form: Injection
Company: Genzyme Corporation
Treatment for: Multiple Sclerosis
Lemtrada (alemtuzumab) is a CD52-directed cytolytic monoclonal antibody indicated for the treatment of relapsing forms of multiple sclerosis (MS).
Development timeline for Lemtrada
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.